Establishing a system-wide assessment of risk process for investigational drugs
American Journal of Health-System Pharmacy · 09.03.2026
DOI: 10.1093/ajhp/zxag074 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 09.03.2026. Verfasst von Kevin Zinchuk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Investigational Drug Service, Brigham and Women's Hospital, Boston, MA, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Purpose
To describe the development and implementation of a standardized, pharmacy-led assessment of risk (AOR) process for investigational products (IPs) in compliance with United States Pharmacopeia (USP) chapter <800> across a large academic health network. Summary USP <800> mandates institutions to maintain a hazardous drug list but offers limited guidance for investigational agents. The US National Institute for Occupational Safety and Health (NIOSH) has a published list of hazardous drugs that institutions should reference. However, the list only includes agents approved through December 2015, leaving a large gap in hazardous drug standardization for marketed products, providing less precedent for those working with investigational agents. In response, a multidisciplinary workgroup led by pharmacy services developed a system-wide IP AOR process. Two distinct tools incorporating toxicological and biosafety criteria were created to assess small-molecule and biopharmaceutical agents. A centralized database and oversight committee were established to ensure consistency, transparency, and regulatory compliance. As of July 2025, 255 IPs were assessed: 8 high-risk hazardous, 126 low-risk hazardous, and 121 nonhazardous agents. The process has enabled appropriate labeling, safe handling, and efficient review workflows across research pharmacies.
Conclusion
The IP AOR process demonstrates the essential role of pharmacists in operationalizing USP <800> requirements for investigational drugs. This model supports occupational safety, regulatory compliance, and scalable implementation across health systems engaged in clinical research. The process outlined in this manuscript is applicable to both investigational agents and any newly marketed drugs being brought into an institution that haven’t been reviewed by NIOSH for inclusion on their list.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Investigational Drug Service, Brigham and Women's Hospital, Boston, MA, USA.
- Clinical Trial Pharmacy, Massachusetts General Hospital, Boston, MA, USA.
- Tufts Medical Center, Boston, MA, USA.
Zitieren
APA
Zinchuk, K., Volf, H., Li, K., Bekelian, E., Lam, J., Manners, S., Silverman, J., & Sanil, N. (2026). Establishing a system-wide assessment of risk process for investigational drugs. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxag074
Vancouver
Zinchuk K, Volf H, Li K, Bekelian E, Lam J, Manners S, et al. Establishing a system-wide assessment of risk process for investigational drugs. American Journal of Health-System Pharmacy. 2026. doi:10.1093/ajhp/zxag074
BibTeX
@article{Zinchuk2026,
author = {Zinchuk, Kevin and Volf, Helen and Li, Kay and Bekelian, Elizabeth and Lam, Jenny and Manners, Stephanie and Silverman, Jon and Sanil, Nitasha},
title = {Establishing a system-wide assessment of risk process for investigational drugs},
journal = {American Journal of Health-System Pharmacy},
year = {2026},
doi = {10.1093/ajhp/zxag074}
}
EUVIMED